Figure 12.

Sensitizing the resistant cells to the effect of ruxolitinib by silencing identified alternative proteins: Lipofectamine® 2000 was used for siRNA silencing of JAK3 in MDA-MB-231 cells surviving 4 × LC50 concentrations ruxolitinib (A), and Akt1 in MDA-MB-468 cells with acquired resistance to ruxolitinib (B). The LC50 values were calculated in naïve cells, naïve cells exposed to siRNA targeting the alternative protein, resistant cells, resistant cells exposed to scrambled siRNA, and resistant cells exposed to siRNA targeting the alternative protein. The LC50 values were calculated via the same sigmoidal effect (% cell death) model and are summarized in corresponding tables. The silencing of targeted alternative protein was confirmed via Western Blot.